Skip to main
BCDA
BCDA logo

BioCardia Inc. (BCDA) Stock Forecast & Price Target

BioCardia Inc. (BCDA) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BioCardia Inc. is advancing its CardiAMP autologous mononuclear cell therapy platform, which has demonstrated significant reductions in heart death equivalents and major adverse cardiovascular and cerebrovascular events (MACCE) in high-risk patients through a Phase 3 clinical trial. The company’s therapies are associated with improved quality of life and decreased mortality rates when used alongside existing heart failure medications, indicating strong potential for long-term benefits in managing ischemic heart failure and refractory angina. Additionally, the ongoing enrollment for CardiALLO, the allogeneic mesenchymal stem cell therapy, further supports BioCardia's growth potential in addressing unmet medical needs in the cardiovascular and pulmonary disease sectors.

Bears say

BioCardia Inc is facing significant challenges, as its CardiAMP HF therapy failed to meet critical clinical endpoints, which raises concerns about the viability of the treatment. The lack of projections for the CardiALLO program further complicates the company’s ability to secure adequate funding, crucial for progressing its therapeutic developments. Additionally, the potential for dilutive capital raises exacerbates the financial uncertainty surrounding the company’s future performance.

BioCardia Inc. (BCDA) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioCardia Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioCardia Inc. (BCDA) Forecast

Analysts have given BioCardia Inc. (BCDA) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BioCardia Inc. (BCDA) has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioCardia Inc. (BCDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.